Despite this growing interest on drug encapsulation into metallocages as drug-delivery systems, the research on the drug adsorption/release processes is still in its infancy, and further studies are necessary to explore their uses in medicinal chemistry. In addition, uorescent coordination cages, especially for the cages that turn-on their uorescence in response to external stimuli, are very attractive for both therapeutic and imaging applications in the medicinal chemistry eld, because they allow in vitro or in vivo imaging without specic handling.
Self-assembled coordination cages with well-dened geometries and cavities have attracted much attention due to their potential applications in molecular recognition, catalytic reactions, biochemistry, and medicine.
1 Concerning medicinal studies, metallocages are promising drug delivery carriers, which can interact with biomolecules, possess anticancer activity, and increase solubility in biological media.
2 Recent reports have demonstrated that coordination cages can act as effective hosts for medicinal guests and have interesting biological properties.
3
For example, Therrien et al. reported the rst coordination cage, an arene-ruthenium-based metallocage, used as drug-delivery system, which showed anticancer effects against human A2780 ovarian cancer cells upon encapsulation of Pd and Pt acetylacetonato complexes.
3a Lippard et al. developed a new strategy to use a hexanuclear supramolecular Pt II cage as a drug delivery vehicle to deliver Pt IV prodrugs to cancer cells. 3b Briken and Isaacs et al. described that metal-organic polyhedron capped with cucurbit [8] uril could deliver doxorubicin to cancer cells and enhance the cytotoxicity, which was ascribed to a combination of increased cellular uptake of cage and doxorubicin release. Despite this growing interest on drug encapsulation into metallocages as drug-delivery systems, the research on the drug adsorption/release processes is still in its infancy, and further studies are necessary to explore their uses in medicinal chemistry. In addition, uorescent coordination cages, especially for the cages that turn-on their uorescence in response to external stimuli, are very attractive for both therapeutic and imaging applications in the medicinal chemistry eld, because they allow in vitro or in vivo imaging without specic handling. 4 Therefore, the design of self-assembled cages that ensure the uorescence response upon the release of an active molecule is more desirable.
Calixarenes are an important class of macrocyclic host molecules in supramolecular chemistry. Calixarene derivatives have been used for the recognition of various molecular species, such as sugars, amino acids, peptides, proteins, and nucleic acids, 5 which are basic substrates in biological processes, and also used in drug delivery investigations.
6 In terms of the calixarene cavity and cage cavity to encapsulate the guests, calixarene-based coordination cages may be employed as drug delivery systems through hydrophobic effects and/or ion-dipole or hydrogen bonding interactions. 7 Moreover, compared with smaller sized coordination complexes studied previously (<1.5 nm), the larger sized calixarene-based supramolecular cages should exhibit slower renal clearance and longer circulation, which would be helpful for theranostic applications, because particle size inuences the clearance rate of nanoparticles from the bloodstream.
8 Only a few reports on the biological properties of calixarene-based nanoscale cages (>2.0 nm) have appeared. 7, 9 Recently, Liao and Hu et al. synthesized an extralarge octahedral coordination cage based on Co 4 -p-tert-butylsulfonyl calix [4] arene. The calixarene-based cage demonstrated good adsorption properties towards a small drug molecule, ibuprofen (Ibu), and the Ibu release experiment revealed that the cage exhibited a slow drug release behavior.
9 Despite the remarkable size and well-known inclusion properties of calixarene-based cages, studies of their applications in drug delivery are rare.
Therefore, in this work, in order to obtain uorescent calixarene-based nanoscale cages, we designed two selfassembled nanocapsules Zn 4 L1 2 and Cd 4 L1 2 based on upper rim terkis-phenyl-terpyridine substituted calix [4] arene derivatives which showed uorescence properties due to the coordination bond of terpyridine (tpy) 11 On the other hand, to evaluate the capability of these cages as drug carriers, mercaptopurine was chosen as the drug guest. Mercaptopurine is a medication used for cancer and autoimmune diseases, 12 the interactions of which with cage have rarely been thorough studied in the eld of host-guest chemistry.
Herein, two highly symmetrical molecular capsules were constructed by dimerization of tpy-containing calixarene derivatives utilizing a Zn(II)/Cd(II)-tpy interaction for the rst time. The D 4h -structures and binding property of two Zn 4 L1 2 and Cd 4 L1 2 cages with mercaptopurine drug were investigated by NMR spectra, ESI-TOF-MS, AFM, UV-Vis and uorescent spectra, and DFT calculations. The releasing drug experiments were carried out, revealing that nanoscale Zn 4 L1 2 and Cd 4 L1 2 cages can signicantly delay release of mercaptopurine into the simulated body liquids.
In order to acquire capsules with nanoscale inner space, an upper rim terkis-terpyridine substituted calix [4] arene (L1) was used for constructing the capsules. Ligand 1 could be obtained according to our report.
13
The two nanocapsules Zn 4 L1 2 (OTf) 8 and Cd 4 L1 2 (OTf) 8 could be obtained as yellow precipitation by adding a THF solution of L1 to a THF solution of zinc(II) or cadmium(II) triuoromethanesulfonate (OTf À ) with ligand/metal molar ratio of 1 : 2 (Scheme 1). The counter-ions could be exchanged by adding a methanol of ammonium hexauorophosphate (PF 6 À ) to the acetonitrile solution of Cd 4 L1 2 to give Cd 4 L1 2 (PF 6 ) 8 . All of the capsules were soluble in MeCN-d 3 , and then their NMR spectra were measured and showed in Fig. 1 8 ( Fig. 1) showed the expected peaks of a tpy-metal complex. In the aromatic region, there were ve sets of aromatic protons from tpy units, two sets from phenyl groups, and a single peak from calixarene, which were in agreement with the desired structure. The protons at 4,4 00 , 5,5 00 , and 6,6 00 -position of tpy dramatically shied upeld because the formation of complex led to the electron shielding effect. (Fig. S5 †) . Several attempts to obtain diffraction quality single crystals of Zn 4 L1 2 were unsuccessful. To incur further insight into the Scheme 1 The synthesis of calix [4] arene based nanocapsules. Fig. 1 structural features, we obtained energy optimized structure of Zn 4 L1 2 using DFT (B3LYP, LANL2DZ) calculations. As illustrated in Fig. 4a and Table S1 , † a cage in an approximate square bipyramid was constructed when the upper rims of two calix [4] arenes were close to each other and captured four Zn 2+ ions. Six coordination bonds existed between each Zn 2+ ion and each two terpyridine groups from two individual calix [4] arene arms. Four Zn 2+ complex units were tightly interlocked into an approximate square through four p-p interactions between terpyridine groups of each adjacent Zn 2+ complex unit. In fact, L1 was not favored for a dimer capsule and thus there was tension in the dimer capsules. Molecular modelling showed the structure distortion of the dimer was mostly neutralized by bending the phenyl group between calixarene and terpyridine. Therefore, the ligand bending was the major contribution to accommodate the strain. As additional evidence, the images from AFM showed the morphology of the dimer cage Zn 4 L1 2 as cone-shape dots on the mica surface (Fig. S6 †) . The measured height of these dots exhibited two different values: 3.9 AE 0.2 nm and 2.2 AE 0.3 nm, which were larger than cage height (3.1 nm) and length (2.0 nm) shown in molecular modelling, respectively, due to the unavoidable tip broadening effect. The host-guest properties of the dimer capsules and mercaptopurine were evaluated in solution. Aer the dimer capsules were dissolved in an aqueous acetonitrile solution (MeCN/H 2 O ¼ 2/1), excessive mercaptopurine solids were added and stirred at room temperature for 2 h, and then the ltrate was separated for NMR and ESI-TOF-MS measurement. Considering the Cd-capsules had well-resolved signals and similar inclusion ability to Zn-capsules, Cd 4 L1 2 were substituted for Zn 4 L1 2 to study the binding interaction between the dimer capsules and mercaptopurine by 1 H NMR (Fig. S7 †) and 1 H DOSY spectra (Fig. S8 †) H signals of host and guest, which further supported the formation of an inclusion complex. Integration of the guest peaks indicated the cages could accommodate about four mercaptopurine guests (Fig. S8 †) . These observations were consistent with what has been observed in other cases of hydrophobic guest binding in water.
14 In addition, we tried to obtain further information on the stoichiometry of the host-guest interaction from ESI-MS experiments of the hostguest mixtures. As seen in Fig. S9 and S10, † the MS signals showed a series of binding species between Cd 4 L1 2 /Zn 4 L1 2 and mercaptopurine with a general formula of [n(mercaptopurine) @Cd 4 L1 2 /Zn 4 L1 2 ] (n # 7), which exhibited higher stoichiometries than that observed for 1 H NMR measurements (n z 4). This suggested that the host-guest interaction of mercaptopurine and cage was strong. In addition to observing tightly bound mercaptopurine guests, the presumably weaker association of mercaptopurine with the exohedral binding sites on the exterior surface of the dimer cages could be detected because in the gas phase charged metallocages might produce ions related to extracage association of guests to the metal ions under the conditions of the mass spectral analysis. Similar mass spectra results were also observed in the reported literature. 15 The control experiments of association of mercaptopurine with Zn(II)(phenyltpy) 2 (CF 3 SO 3 ) 2 and 25,26,27,28-tetrabutoxycalix[4] arene have been performed. As seen from Fig. S11 , † no obvious shis were observed in 1 H NMR spectra of the mixture, compared with that of 25,26,27,28-tetrabutoxycalix[4] arene, mercaptopurine, and Zn(II)(phenyl-tpy) 2 (CF 3 SO 3 ) 2 , respectively, supporting encapsulation of the guest molecules inside of the Zn 4 L1 2 cage.
From 1 H NMR spectra (Fig. S8 †) , we speculated four mercaptopurine molecules could be encapsulated into the Zn 4 L1 2 cage. To further clarify stoichiometry of the mercaptopurine@Zn 4 L1 2 complex and explore their interaction modes, molecular simulation was executed in this drug-cage supramolecular system of mercaptopurine@Zn 4 L1 2 and the results of their geometry optimization were shown in Fig. 4b and Tables S2 and S3. † As illustrated in Fig. 4b , each pyramid unit encapsulated two mercaptopurine molecules. In one pyramid unit, one mercaptopurine orientated to cavity was captured by calix [4] arene cavity and two arms of the cage with three S-p interactions (3.93, 4.08 and 4.37Å), one S-H-p interaction (4.37 A) and one p-p interaction (4.55Å). The other mercaptopurine was caught by the adjacent mercaptopurine and two arms of the cage with one S-p interactions (4.08Å) and three p-p interactions (4.08, 4.47 and 4.76Å) . In another pyramid unit, there were similar interactions between the two encapsulated mercaptopurine molecules and the cage. There are two S-p interactions (3.95 and 4.25Å), one S-H-p interaction (4.25Å) and three p-p interactions (4.20, 4.55 and 4.58Å) between the cage and the one mercaptopurine deepened into calix [4] arene cavity. And there are one S-p interactions (4.12Å) and three p-p interactions (4.20, 4.27 and 4.52Å) between the cage and the other mercaptopurine caught by the neighboring mercaptopurine. No coordination interaction appeared between mercaptopurine and Zn
2+
. Correspondingly, the symmetric geometrical structure of the cage was remarkably distorted in order to match the interactions with mercaptopurine. Moreover, the p-p interactions between adjacent terpyridine groups partially disappeared although the coordination interactions between terpyridine groups and Zn 2+ still existed. Meanwhile, the stabilization energy À45.3 kcal mol À1 (see Table S3 †) of 4(mercaptopurine)@Zn 4 L1 2 complex also conrmed the fact that four mercaptopurines can be stably captured by the cage. It is well known that UV/Vis and uorescent spectra are powerful methods for host-guest inclusion study. Therefore, the UV/Vis and uorescent spectra of the Zn-capsules upon the addition of mercaptopurine were measured. In the absorption spectra, the titration of Zn 4 L1 2 with mercaptopurine resulted in the decrease of the absorption intensity at 256 nm and 366 nm, respectively, and increase of the intensity at 236 nm and 328 nm with a blue-shi, respectively, while the three isosbestic points at 247 nm, 285 nm, and 350 nm appeared, indicating complex formation (Fig. 5a) . Interestingly, the Zn 4 L1 2 cage exhibited excellent uorescent properties. In the uorescent spectrum of Zn 4 L1 2 , the maximum excitation and emission wavelengths were observed at 340 and 600 nm, respectively. The uorescence titration of Zn 4 L1 2 with mercaptopurine showed a gradual decrease in the emission band at 600 nm with a slight blue-shi within 5 nm over mercaptopurine concentrations range of 6 Â 10 À4 to 7 Â 10 À2 mM, which conrmed the interaction between Zn 4 L1 2 and mercaptopurine further (Fig. 5b) . Moreover, the interaction provided a uorescence quenching pathway by the excitation energy transfer or charge transfer from Zn 4 L1 2 to the mercaptopurine guests. It is desirable that the Zn 4 L1 2 cages can make a uorescence turn-on response upon the release of mercaptopurine. Since Zn 4 L1 2 has lower toxicity in comparison to Cd 4 L1 2 , Zn 4 L1 2 was chosen as candidate to test its drug delivery property. It is known that drug-carrying materials with the nanometer size can achieve effective drug delivery. Nanoscale mercaptopurine@Zn 4 -L1 2 cages have been prepared by the method described above, and the loading amount was determined by 1 H NMR. As seen from Fig. S12 , † the loading amount of mercaptopurine encapsulated in Zn 4 L1 2 cages was estimated to be 13.0 AE 0.2 wt%, corresponding to [4(mercaptopurine) 
To simulate drug sustained-release in human body liquid, the release of mercaptopurine from the mercaptopurine@Zn 4 -L1 2 nanoparticles was performed in phosphate buffer solution (PBS, pH ¼ 7.4) with dialysis bag and detected by UV/Vis spectrum. The release amount was calculated according to the calibration plots of standard curve of pure mercaptopurine in PBS. The mercaptopurine-loaded Zn 4 L1 2 samples used for the release experiments weighed 10.0 mg and 0.61 mg of Ibu was released from the sample. The release process was considered in two stages within 45 hours (Fig. 6 ). In the rst stage (8 h), 0.35 mg of Ibu was released in the rst stage and in the second stage 0.26 mg in the next 37 hours. The drug release became very slow aer 45 hours. These release behaviors were similar to those for the reported coordination cages. 9, 16 For comparison, the pure mercaptopurine in solid state was dialyzed as a controlexperiment which indicated that up to 95% of the total mercaptopurine was quickly released within 3 hours. These results suggested that the cage structures of Zn 4 L1 2 protracted the release of mercaptopurine. The slow release may be due to the slow diffusion rate of mercaptopurine from the windows of the cavities owing to the strong interaction of S-p and the p-p interactions between mercaptopurine and the aromatic skeleton of Zn 4 L1 2 .
Conclusions
In conclusion, we have designed a uorescent system, in which two capsule-like highly symmetrical cage (Zn 4 L1 2 and Cd 4 L1 2 ) based on calixarene were almost quantitatively constructed in a self-assembled manner by a terpyridine-M II -terpyridine (M ¼ Zn and Cd) interaction. The nanoscale cages could encapsulate the anticancer drug mercaptopurine, as shown by NMR spectroscopy, AFM and ESI-TOF-MS. UV/Vis and uorescent spectra conrmed the binding interaction and uorescence switch behaviors between Zn 4 L1 2 and mercaptopurine further. Moreover, the theoretical simulation analysis veried the S-p and pp interactions between the cage and mercaptopurine guests, in agreement with the spectroscopic results. Drug release experiment in PBS buffer solution demonstrated that the release process of drug molecules was able to last for 45 hours, effectively retarding burst release of mercaptopurine, which make these cages suitable candidates as drug carriers.
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